Emma Laporte

GynQura Therapeutics: harnessing patient-derived organoids to develop first-in-class, disease-modifying therapeutics to revolutionize the treatment of endometriosis.

We develop and use patient-derived organoids (PDOs), from women with endometriosis and healthy controls, to identify and validate therapeutically relevant targets and screen novel drug candidates, to build a pipeline of disease-modifying therapeutics that effectively target different types and stages of endometriosis.

In this project, drug targets are identified using transcriptomic, bioinformatic and AI-driven approaches. Identified drug targets are validated in the PDOs by performing target-specific knock-down or knock-out and assessing the phenotypic effect.